G-CSF 和 G-CSF 生物相似藥市場規模、佔有率和成長分析：按藥物類型、治療應用、通路和地區分類－2026-2033 年產業預測

2024年全球G-CSF和G-CSF生物相似藥市場價值為56億美元，預計將從2025年的60.3億美元成長到2033年的108.3億美元。預測期（2026-2033年）的複合年成長率預計為7.6%。

全球粒細胞集落刺激因子 (G-CSF) 及其生物相似藥市場的主要驅動力是原生物製藥專利到期以及對價格合理的腫瘤支持治療日益成長的需求。已上市的 G-CSF 產品已展現出顯著的臨床療效，推動了 Zarchio 和 Udenica 等生物相似藥的出現。這些生物相似藥促進了價格競爭，並擴大了患者的用藥範圍。這種轉變使市場對價格更加敏感，促使醫院採用成本較低的生物相似藥。因此，治療依從性提高，住院率下降。此外，人工智慧的應用改善了需求預測和生產流程，提高了營運效率，進一步降低了價格。因此，該市場對生產投資和新興應用的探索更具吸引力，為該領域的永續成長鋪平了道路。

推動全球G-CSF和G-CSF生物相似藥市場發展的因素

癌症患者數量的不斷成長，以及骨髓抑制化療的廣泛應用，顯著增加了臨床上對預防和治療化療引起的嗜中性白血球低下症治療方法的需求。這一趨勢正在推動粒細胞集落刺激因子（G-CSF）及其生物相似藥市場的成長。臨床指引和醫療機構的實踐強調了預防性和治療性給藥對於維持治療強度和最大限度降低感染風險的重要性，從而導致處方頻率的增加。此外，隨著臨床醫師對生物相似藥的了解不斷加深，以及醫療機構採用整合這些藥物的通訊協定，未被滿足的醫療需求正得到有效滿足，從而推動市場持續擴張。

全球粒細胞集落刺激因子（G-CSF）和G-CSF生物相似藥市場面臨的限制因素

全球粒細胞集落刺激因子（G-CSF）及其生物相似藥市場面臨許多挑戰，主要原因是各國對相似性的監管要求複雜多樣，且在互通性方面標準不一。這些因素造成了複雜的局面，可能阻礙潛在研發者的積極性，並延緩產品進入各個市場。研發者需要進行全面的對比試驗，履行核准後監測職責，並適應不斷變化的法規，所有這些都需要延長研發週期，並持續投入資金用於證據收集和與監管機構溝通。這種複雜的核准流程最終阻礙了新生物相似藥的上市，並限制了可能推動市場更廣泛滲透和成長的競爭動力。

全球粒細胞集落刺激因子（G-CSF）及G-CSF生物相似藥市場趨勢

全球粒細胞集落刺激因子（G-CSF）及其生物相似藥市場正經歷著向門診治療的顯著轉變，這主要得益於醫療系統和腫瘤中心將支持性治療轉移到家庭環境中。這一趨勢優先考慮患者的便利性，旨在減少住院需求，迫使生產商創新給藥配方、開發個人化患者支持方案並加強門診治療的物流保障。此外，專業藥局與醫療服務提供者之間的合作對於確保患者用藥依從性和監測至關重要。隨著分散式治療逐漸成為標準，人們對整個G-CSF價值鏈的穩定性、易用性和一體化服務的要求也日益提高，從而影響著市場動態。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

市場考察

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場吸引力指數
• PESTEL 分析
• 監理情勢

全球粒細胞集落刺激因子 (G-CSF) 及 G-CSF 生物相似藥市場規模：按藥物類型和複合年成長率 (2026-2033) 分類

• G-CSF
• 生物相似藥
• 荷爾蒙
• 其他

全球粒細胞集落刺激因子 (G-CSF) 及 G-CSF 生物相似藥市場規模：依治療應用及複合年成長率 (2026-2033) 分類

• 腫瘤學
• 血液疾病
• 慢性病
• 內分泌疾病
• 其他

全球粒細胞集落刺激因子 (G-CSF) 及 G-CSF 生物相似藥市場規模：按分銷管道和複合年成長率 (2026-2033) 分類

• 網路藥房
• 離線
  • 醫院藥房
  • 零售藥房

全球粒細胞集落刺激因子及粒細胞集落刺激因子生物相似藥市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 2023-2025年營收年比比較

主要企業簡介

• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Sandoz International GmbH
• Mylan NV
• Pfizer Inc.
• BioGeneriX AG
• Intas Pharmaceuticals Ltd.
• Biocon Limited
• Celltrion Healthcare Co., Ltd.
• Fresenius Kabi AG
• Zydus Cadila
• Accord Healthcare Limited
• Hikma Pharmaceuticals PLC
• Dr. Reddy's Laboratories Ltd.
• Novartis AG
• Coherus BioSciences, Inc.
• Emcure Pharmaceuticals Ltd.
• Aurobindo Pharma Limited
• Samsung Bioepis Co., Ltd.
• GSK plc

結論與建議

Global G-Csf And G-Csf Biosimilars Market size was valued at USD 5.6 Billion in 2024 and is poised to grow from USD 6.03 Billion in 2025 to USD 10.83 Billion by 2033, growing at a CAGR of 7.6% during the forecast period (2026-2033).

The global G-CSF and G-CSF biosimilars market is primarily propelled by the expiration of patents for original biologics and the increasing demand for accessible supportive oncology care. Established G-CSF products have shown significant clinical benefits, enabling the emergence of biosimilars like Zarxio and Udenyca, which foster competitive pricing and broaden patient access. This shift has transformed the market into a price-sensitive arena, encouraging hospitals to adopt lower-cost biosimilars, resulting in better treatment adherence and reduced hospitalization rates. Additionally, the integration of AI enhances operational efficiencies by improving demand forecasting and manufacturing processes, further supporting affordability. As a result, the market becomes more attractive for production investments and exploration of emerging applications, paving the way for sustained growth in the sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global G-Csf And G-Csf Biosimilars market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global G-Csf And G-Csf Biosimilars Market Segments Analysis

Global g-csf and g-csf biosimilars market is segmented by drug type, therapeutic application, distribution channel and region. Based on drug type, the market is segmented into G-CSF, Biosimilars, Hormones and Others. Based on therapeutic application, the market is segmented into Oncology, Blood Disorders, Chronic Diseases, Endocrine Disorders and Others. Based on distribution channel, the market is segmented into Online Pharmacies and Offline. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global G-Csf And G-Csf Biosimilars Market

The increasing prevalence of cancer, coupled with the extensive use of myelosuppressive chemotherapy, has significantly heightened the clinical demand for treatments that prevent and manage chemotherapy-induced neutropenia. This trend is driving growth in the G-CSF and biosimilars market. Clinical guidelines and the practices of healthcare providers highlight the importance of both preventive and therapeutic administration to sustain treatment intensity and minimize the risk of infections, leading to more frequent prescriptions. Additionally, as clinicians become more acquainted with biosimilar options and institutions adopt protocols integrating these drugs, unmet clinical needs are being effectively addressed, resulting in sustained market expansion.

Restraints in the Global G-Csf And G-Csf Biosimilars Market

The Global G-CSF and G-CSF biosimilars market faces significant challenges due to complex and varied regulatory requirements for demonstrating similarity, coupled with differing national standards for interchangeability. These factors contribute to an intricate landscape that can discourage potential developers and delay the introduction of products to various markets. Developers are required to create comprehensive comparative studies, fulfill post-approval monitoring responsibilities, and adapt to constantly changing regulations, all of which can extend development timelines and necessitate ongoing investments in both evidence generation and regulatory dialogue. This intricate approval process ultimately hinders the entry of new biosimilars, limiting competitive dynamics that could otherwise drive broader adoption and growth in the market.

Market Trends of the Global G-Csf And G-Csf Biosimilars Market

The Global G-Csf and G-Csf Biosimilars market is witnessing a significant shift towards outpatient therapies, driven by healthcare systems and oncology centers transitioning supportive care to home-based settings. This trend prioritizes patient convenience and aims to reduce inpatient demand, prompting manufacturers to innovate delivery formats, create tailored patient support programs, and enhance logistics for ambulatory care. Additionally, partnerships between specialty pharmacies and healthcare providers are becoming essential to ensure patient adherence and monitoring. As decentralized care becomes the norm, there is an increasing expectation for stability, ease of use, and integrated services throughout the G-Csf value chain, shaping market dynamics.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global G-CSF and G-CSF Biosimilars Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• G-CSF
• Biosimilars
• Hormones
• Others

Global G-CSF and G-CSF Biosimilars Market Size by Therapeutic Application & CAGR (2026-2033)

• Market Overview
• Oncology
• Blood Disorders
• Chronic Diseases
• Endocrine Disorders
• Others

Global G-CSF and G-CSF Biosimilars Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Online Pharmacies
• Offline
  • Hospital Pharmacies
  • Retail Pharmacies

Global G-CSF and G-CSF Biosimilars Market Size & CAGR (2026-2033)

• North America (Drug Type, Therapeutic Application, Distribution Channel)
  • US
  • Canada
• Europe (Drug Type, Therapeutic Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Therapeutic Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Therapeutic Application, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Therapeutic Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioGeneriX AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celltrion Healthcare Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Accord Healthcare Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coherus BioSciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emcure Pharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Bioepis Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations